Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098436 · ClinicalTrials.gov registry record · Phase 1
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
A Phase 1 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00098436 is a Phase 1 study that has completed, run by Vion Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT00098436, a Phase 1 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temozolomide may also help VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug. Giving temozolomide together with VNP40101M may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide and VNP40101M in treating patients with relapsed or refractory leukemias.
Interventions
- DRUG temozolomide
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098436
The ClinicalTrials.gov registry entry for NCT00098436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00098436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098436 about?
NCT00098436 is a clinical study titled "Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias". RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temozolomide may also help VNP40101M kill more cancer cells by making cancer cells more sensitive to th...
What is the current status of trial NCT00098436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-09. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00098436?
The interventions under investigation include: temozolomide (DRUG), laromustine (DRUG).
Who is sponsoring clinical trial NCT00098436?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.